Effect of visual impairment on depression and anxiety during the COVID-19 pandemic in the United States.

OBJECTIVE

To evaluate associations between visual impairment, anxiety, and depression during the COVID-19 pandemic in the US.

DESIGN

Retrospective cross-sectional

METHODS

This study included a cohort of US adults enrolled in the National Institute of Health All of Us Research Program. Individuals who were blind/visually impaired (BVI) were identified via SNONMED codes and compared to a control cohort. Prevalence of baseline, new, and worsened depression and anxiety, as defined by SNONMED codes and medication use were compared between the two groups. Anxiety and depression during the COVID-19 pandemic were evaluated using the Generalized Anxiety Disorder 7 and the Patient Health Questionnaire 9 survey, respectively.

RESULTS

324,915 participants, (7,526 BVI individuals and 317,389 controls) were included. BVI individuals had higher prevalence of baseline anxiety and depression (50.4% vs. 28.7%, p<0.001), new anxiety and depression (0.98% vs. 0.66%, p<0.001), and worsened anxiety and depression throughout the COVID-19 pandemic (0.19% vs. 0.07%, p<0.001) compared to controls. Being BVI was significantly associated with baseline and worsened anxiety and depression, after controlling for age, gender, race, ethnicity, and comorbidity (adjusted odds ratio (aOR)=1.61; 95% CI 1.46-1.78, aOR=2.07; 95% CI 1.03-4.13). Similarly, being BVI was associated with a 2.07-point increase on the GAD-7 survey (adjusted beta=2.07; 95% CI 1.32-3.27) and a 2.96-point increase on the PHQ-9 survey (adjusted beta=2.96; 95% CI 1.64-5.36).

CONCLUSIONS

These findings indicate that BVI individuals are disproportionately affected by anxiety and depression at baseline and throughout the pandemic, highlighting an important need to promote access to mental health services among this population.